DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ALITRETINOIN

« Back to Dashboard

Clinical Trials for Alitretinoin

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00002188	A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma	Completed	Ligand Pharmaceuticals	Phase 2	The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS).
NCT00002188	A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma	Completed	Anderson Clinical Research	Phase 2	The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS).
NCT00002439	A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma	Completed	Ligand Pharmaceuticals	N/A	The purpose of this study is to see if ALRT1057 gel is safe and effective in treating Kaposi's sarcoma (KS) when applied to skin .
NCT00002439	A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma	Completed	Anderson Clinical Research	N/A	The purpose of this study is to see if ALRT1057 gel is safe and effective in treating Kaposi's sarcoma (KS) when applied to skin .
NCT00124436	Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis	Completed	Basilea Pharmaceutica	Phase 3	Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to >75% of the baseline disease severity, will be investigated for response to further treatment with alitretinoin. Also, patients who have responded with mild or moderate disease will be investigated for additional treatment effect after prolongated treatment.
NCT00124475	Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis	Completed	Basilea Pharmaceutica	Phase 3	The purpose of the study is to determine the therapeutic effect of alitretinoin, a retinoid, on severe, therapy refractory chronic hand dermatitis.
NCT00309621	Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis	Completed	Basilea Pharmaceutica	Phase 3	Patients with severe chronic hand dermatitis, that has not responded to topical treatment, including topical steroids and the avoidance of aggravating factors, will be treated with the oral medication alitretinoin. The study aims to investigate the safety and efficacy of the medication when given over a period of 6 months.

Clinical Trial Conditions for Alitretinoin

Condition Name

Condition Name for Alitretinoin
Intervention	Trials
Hand Dermatoses	3
Eczema	2
HIV Infections	2
Sarcoma, Kaposi	2

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Alitretinoin
Intervention	Trials
Eczema	5
Dermatitis	4
Skin Diseases	3
Hand Dermatoses	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Alitretinoin

Trials by Country

Trials by Country for Alitretinoin
Location	Trials
United States	32
Germany	11
Canada	6
Netherlands	3
Denmark	3

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Alitretinoin
Location	Trials
California	1
New Hampshire	1
District of Columbia	1
Florida	1
Georgia	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Alitretinoin

Clinical Trial Phase

Clinical Trial Phase for Alitretinoin
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	8
Phase 2	4

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Alitretinoin
Clinical Trial Phase	Trials
Completed	11
Recruiting	3
Terminated	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Alitretinoin

Sponsor Name

Sponsor Name for Alitretinoin
Sponsor	Trials
Basilea Pharmaceutica	6
Ligand Pharmaceuticals	2
University Hospital, Gentofte, Copenhagen	2

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Alitretinoin
Sponsor	Trials
Industry	14
Other	14

Export unavailable in trial.
Subscribe for complete access.